Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactions

Radiology

Volumn 266, Issue 3, 2013, Pages 773-782

  Davenport, Matthew S ^a   Dillman, Jonathan R ^a   Cohan, Richard H ^a   Hussain, Hero K ^a   Khalatbari, Shokoufeh ^a   McHugh, Jonathan B ^a   Ellis, James H ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOFOSVESET; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIDOL; GADOXETIC ACID;

ADOLESCENT; ADULT; AGED; ALLERGIC LIKE REACTION; ANAPHYLACTIC SHOCK; ARTICLE; CARDIOPULMONARY COLLAPSE; CHILD; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FACE EDEMA; FEMALE; HUMAN; LARYNX EDEMA; MAJOR CLINICAL STUDY; MALE; NOSE OBSTRUCTION; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SNEEZING; STATISTICAL ANALYSIS; STRIDOR; THROAT IRRITATION; URTICARIA; WHEEZING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CONTRAST MEDIA; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; FEMALE; GADOLINIUM DTPA; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MICHIGAN; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874327730     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12120253     Document Type: Article

References (25)

1. Public health advisory: gadolinium-containing contrast agents for magnetic resonance imaging (MRI). http://www.fda.gov/Drugs/ DrugSafety/ ucm223966.htm. Originally published June 8, 2006. Updated December 2010. Accessed August 18, 2011.
2. Thomsen HS, Marckmann P, Logager VB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 2007; 7: 130-137.
3. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243(1): 148-157.
4. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21(4): 1104-1108.
5. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17(9): 2359-2362.
6. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007;242(3): 647-649.
7. Thomsen HS, Morcos SK, Dawson P. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol 2006;61(11): 905-906.
8. American College of Radiology. Manual on contrast media. 7th ed. Reston, Va: American College of Radiology, 2011.
9. ESUR Guidelines on Contrast Media, v 7.0: very late adverse reactions. http://www .esur.org/Contrast-media.51.0.html; Accessed August 18, 2011.
10. Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC. Frequency and severity of acute allergic-like reactions to gadoliniumcontaining i.v. contrast media in children and adults. AJR Am J Roentgenol 2007;189(6): 1533-1538.
11. Prince MR, Zhang H, Zou Z, Staron RB, Brill PW. Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol 2011;196(2):W138-W143.
12. Abujudeh HH, Kosaraju VK, Kaewlai R. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections. AJR Am J Roentgenol 2010;194(2): 430-434.
13. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP, eds. Advances in inflammation research, Vol 6. New York, NY: Raven, 1984; 1-7.
14. Hartnell NR, Wilson JP, Patel NC, Crismon ML. Adverse event reporting with selective serotonin-reuptake inhibitors. Ann Pharmacother 2003;37(10): 1387-1391.
15. Wallenstein EJ, Fife D. Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited. Drug Saf 2001;24(3): 233-237.
16. Freed KS, Leder RA, Alexander C, DeLong DM, Kliewer MA. Breakthrough adverse reactions to low-osmolar contrast media after steroid premedication. AJR Am J Roentgenol 2001;176(6): 1389-1392.
17. Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC. Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine premedication. AJR Am J Roentgenol 2008;190(1): 187-190.
18. Davenport MS, Cohan RH, Caoili EM, Ellis JH. Repeat contrast medium reactions in premedicated patients: frequency and severity. Radiology 2009;253(2): 372-379.
19. Package insert. MultiHance (gadobenate dimeglumine injection). Bracco Diagnostics, Princeton NJ. November 2010.
20. Knopp MV, Balzer T, Esser M, Kashanian FK, Paul P, Niendorf HP. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol 2006;41(6): 491-499.
21. Shellock FG, Parker JR, Pirovano G, et al. Safety characteristics of gadobenate dimeglumine: clinical experience from intraand interindividual comparison studies with gadopentetate dimeglumine. J Magn Reson Imaging 2006;24(6): 1378-1385.
22. Murphy KJ, Brunberg JA, Cohan RH. Adverse reactions to gadolinium contrast media: a review of 36 cases. AJR Am J Roentgenol 1996;167(4): 847-849.
23. Bleicher AG, Kanal E. Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. AJR Am J Roentgenol 2008;191(6): W307-W311.
24. Morgan DE, Spann JS, Lockhart ME, Winningham B, Bolus DN. Assessment of adverse reaction rates during gadoteridolenhanced MR imaging in 28,078 patients. Radiology 2011;259(1): 109-116 .
25. Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 2004;24(6): 743-749.